Pascolizumab

Monoclonal antibody

^NY (what is this?) (verify)

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.^[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002.^[2] Development was discontinued as it showed little benefit.^[3]

References

^ Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
^ Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov
^ Bice JB, Leechawengwongs E, Montanaro A (2014). "Biologic targeted therapy in allergic asthma". Annals of Allergy, Asthma & Immunology. 112 (2): 108 - 115. doi:10.1016/j.anai.2013.12.013.

Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors Azathioprine Mycophenolic acid dihydroorotate dehydrogenase inhibitors Leflunomide Teriflunomide antifolate Methotrexate
Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin Ciclosporin Pimecrolimus Tacrolimus Voclosporin Abetimus Gusperimus
IMiDs	Lenalidomide Pomalidomide Thalidomide PDE4 inhibitor Apremilast

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Sirolimus Everolimus Ridaforolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 Eculizumab TNF Adalimumab Afelimomab Certolizumab pegol Golimumab Infliximab Nerelimomab Interleukin Anakinra Basiliximab Bimekizumab Briakinumab Brodalumab Canakinumab Daclizumab Guselkumab Ixekizumab Netakimab Olokizumab Rilonacept Risankizumab Sarilumab Satralizumab Secukinumab Siltuximab Sirukumab Spesolimab Tildrakizumab Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12 and IL-23 Lebrikizumab Ustekinumab IL-17A Secukinumab
Cellular target	CD3 Muromonab-CD3 Otelixizumab Teplizumab Visilizumab CD4 Clenoliximab Keliximab Zanolimumab CD11a Efalizumab CD18 Erlizumab CD20 Obinutuzumab Ocrelizumab Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin Aselizumab CD80 Galiximab CD147/Basigin Gavilimomab CD154 Ruplizumab Frexalimab BLyS Belimumab CAT Bertilimumab Lerdelimumab Metelimumab Integrin Natalizumab Vedolizumab Interleukin-6 receptor Tocilizumab LFA-1 Odulimomab IL-2 receptor/CD25 Basiliximab Daclizumab Inolimomab T-lymphocyte (Zolimomab aritox)
Unsorted	Alemtuzumab Anifrolumab Atorolimumab Begelomab Cedelizumab Emapalumab Fontolizumab Inebilizumab Maslimomab Morolimumab Ofatumumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Teprotumumab Vapaliximab Vepalimomab

Polyclonal

-cept (Fusion)

CTLA-4
- Abatacept
- Belatacept
TNF inhibitor
- Etanercept
- Opinercept
Aflibercept
Alefacept
Rilonacept

Unsorted

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Interleukin receptor modulators

IL-1

Agonists: Interleukin 1 (α, β)
Mobenakin
Pifonakin

Antagonists: AF-12198
Anakinra
IL-1RA
Isunakinra

Antibodies: Canakinumab
Gevokizumab
Lutikizumab

Decoy receptors: Rilonacept (IL-1 Trap)

IL-2

Agonists: Adargileukin alfa
Aldesleukin
Celmoleukin
Denileukin diftitox
Interleukin 2
Pegaldesleukin
Teceleukin
Tucotuzumab celmoleukin

IL-3

Agonists: Daniplestim
Interleukin 3
Leridistim
Milodistim
Muplestim
Promegapoietin

IL-4

Agonists: Binetrakin
Interleukin 4
Interleukin 13

Antagonists: Pitrakinra

Antibodies: Dupilumab
Pascolizumab

IL-5

Agonists: Interleukin 5

Antagonists: YM-90709

Antisense oligonucleotides: TPI ASM8

IL-6

Agonists: Atexakin alfa
Interleukin 6

IL-7

Agonists: Interleukin 7

IL-8

See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.

IL-9

Agonists: Interleukin 9

Antibodies: Enokizumab

IL-10

Agonists: Ilodecakin
Interleukin 10 (CSIF)

IL-11

Agonists: Interleukin 11 (AGIF)
Oprelvekin

IL-12

Agonists: Edodekin alfa
Interleukin 12

Antibodies: Briakinumab
Ustekinumab

IL-13

Agonists: Binetrakin
Cintredekin besudotox
Interleukin 4
Interleukin 13

IL-15

Agonists: ALT-803
Interleukin 15

IL-17

Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)

Antibodies: Brodalumab
Ixekizumab
Perakizumab
Remtolumab
Secukinumab
Vunakizumab

IL-18

Agonists: Iboctadekin
Interleukin 18
Interleukin 37
Tadekinig

Binding proteins: IL18BP

IL-20

Antibodies: Fletikumab (against IL-20)

IL-21

Agonists: Denenicokin
Interleukin 21

Antibodies: NNC0114-0005
NNC0114-0006

IL-22

Agonists: Interleukin 22

Antibodies: Fezakinumab (against IL-22)

IL-23

Agonists: Interleukin 23 (SGRF)

IL-27

Agonists: Interleukin 27 (interleukin 30)

IL-28

Agonists: Interferon λ4 (IFN-λ4)
Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
Interleukin-29 (IFN-λ1)

IL-31

Agonists: Interleukin 31

IL1RL1

Agonists: Interleukin 33

IL1RL2

Agonists: Interleukin 36 (α, β, γ)
Interleukin 38

Antagonists: IL-36RA

Others

JAK	See here instead.
Others	Interleukin 14 (taxilin alpha, HMW-BCGF) Interleukin 16 (signals through CD4) Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer) Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer) Interleukin 32 Interleukin 34 (signals through M-CSFR/CSF1R) Interleukin 35 Unsorted: Efavaleukin alfa Efineptakin alfa